Instinet establishes a vendor search and credit tracker in response to buy-side feedback, ahead of unbundling requirements.
Moving research payments into the post-trade process could help get around conflict between CSAs and RPAs.
Questions raised over viability of CSAs and potential loopholes on non-monetary minor benefits.
As the industry moves to implement more commission sharing agreements, firms may find they fall short of regulatory expectations.
Research payments crackdown won't ban CSAs, provided buy-side breaks down costs for investors.